<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856439</url>
  </required_header>
  <id_info>
    <org_study_id>PS1/001/09</org_study_id>
    <secondary_id>2009-017253-35</secondary_id>
    <nct_id>NCT01856439</nct_id>
  </id_info>
  <brief_title>Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease</brief_title>
  <official_title>A Multicentre, Open-label Study to Determine the Long Term Safety, Tolerability and Efficacy of ProSavin in Patients With Bilateral, Idiopathic Parkinson's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxford BioMedica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oxford BioMedica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to assess the long term tolerability of ProSavin and whether it is safe
      and efficacious in patients administered ProSavin from the PS1/001/07 study .
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the long term safety and tolerability of ProSavin</measure>
    <time_frame>10 years</time_frame>
    <description>The number and severity of any adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients' responses to ProSavin administration</measure>
    <time_frame>10 years</time_frame>
    <description>Assessed using Unified Parkinson's Disease Rating Score(UPDRS) Part III, evaluating percentage of time during waking day that patient is in the &quot;off&quot; state through patient diaries and activities of daily living using PDQ-39 at 36 months post administration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Long term follow up</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Long term follow up of patient's who received ProSavin in previous study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ProSavin</intervention_name>
    <description>Long term follow up of patients who received ProSavin in a previous study</description>
    <arm_group_label>Long term follow up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  must have met all inclusion criteria for study PS1/001/07

          -  willing to have L-DOPA dosage reduced/withdrawn at the discretion of the investigator
             at regular intervals to allow assessment of ProSavin in the absence of concomitant
             antiparkinsonian medication.

          -  affiliated with the French social security health care system (Patients enrolled in
             France only)

          -  signed and dated written informed consent obtained from the patient and/or the
             patient's legally acceptable representative, if applicable, in accordance with the
             local regulations

          -  must have been treated with ProSavin/Sham

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephane Palfi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henri Mondor Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger Barker, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Addenbrookes Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <last_update_submitted>June 9, 2014</last_update_submitted>
  <last_update_submitted_qc>June 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ProSavin</keyword>
  <keyword>Gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

